Movement Alert|Viking Therapeutics Intraday Rise 8.16% in Regular Trading, Recent clinical progress and strong cash position remained in focus

Market Focus11-10

On November 10, Viking Therapeutics rose 8.16% in Regular Trading, trading at $29.01/share, with turnover of $63.90 million.

The most recent company-specific backdrop in public reporting was the late-October update showing a third-quarter EPS loss of $1.55, wider than consensus expectations, alongside positive study data and a cash, cash equivalents, and short-term investments balance of about $960 million. That combination supported investor attention on the company’s ability to keep advancing its obesity pipeline despite near-term earnings pressure.

Recent developments also included the start of the Phase 3 program for oral VK2735 in adults with obesity and earlier maintenance-dosing data indicating that less frequent VK2735 dosing preserved a high proportion of prior weight loss, reinforcing the competitive profile of the lead obesity candidate.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment